Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers
- PMID: 39570822
- PMCID: PMC11581295
- DOI: 10.1371/journal.pone.0314205
Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers
Abstract
Brain metastases are frequent in neuropathology practices; however, the literature on their distribution is frequently derived from imaging studies. This work examined metastases of lung cancer to the brain through the lens of pathology specimens. All brain surgical pathology cases accessioned from 2011-2020 were retrieved from a regional laboratory. Specimens were classified by neuroanatomical location, diagnostic category, and diagnosis with a hierarchical free text string-matching algorithm. All reports classified as probable metastasis per algorithm were reviewed by a pathologist. Lung biomarkers and selected immunostains were retrieved with text parsing and reviewed. Among 4,625 cases of brain surgical resection specimens, 854 were classified as probable metastasis by the algorithm. On report review, 538/854 cases were confirmed as metastasis with a known primary site. The 538 cases were from 511 patients and 234/511 patients had lung primaries. Small cell lung cancer lesions were most frequently found in the cerebellum (17/30). Lesions from lung adenocarcinoma (59/164) and non-small cell carcinoma-not otherwise specified (NSCLC-NOS) (15/34) were most commonly found in the frontal lobe. Squamous cell carcinoma lesions were most commonly found in the frontal and occipital lobes (8/27). 72/234 cases were reported as NSCLC-NOS and could be further subclassified using immunostaining (41/72). Lung biomarker data were retrieved in ~38% of cases. PD-L1 positivity was dependent on neuroanatomical distribution (p = 0.04); other examined biomarkers were not. The distribution of lung tumours metastatic to the brain is dependent on the lung cancer subtype (p<0.001). The reporting of histologic subtype could be further optimized in the local environment.
Copyright: © 2024 Bonert et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.The corresponding author (MB) retains the copyright on the computer code that was written outside of his employment relationship with McMaster University/St. Joseph’s Healthcare Hamilton/Hamilton Regional Laboratory Medicine Program. The above does not in any way limit adherence to the PLOS ONE data availability policy, as found here: https://journals.plos.org/plosone/s/data-availability. There is no financial conflict of interest. There are no conflicts for the other authors.
Figures




Similar articles
-
Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history.PLoS One. 2023 Nov 9;18(11):e0294154. doi: 10.1371/journal.pone.0294154. eCollection 2023. PLoS One. 2023. PMID: 37943775 Free PMC article.
-
Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.Cancer Immunol Immunother. 2021 Apr;70(4):1063-1074. doi: 10.1007/s00262-020-02755-w. Epub 2020 Oct 28. Cancer Immunol Immunother. 2021. PMID: 33113005 Free PMC article.
-
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.Pathol Oncol Res. 2021 Apr 8;27:597499. doi: 10.3389/pore.2021.597499. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34257548 Free PMC article.
-
[Non-small cell lung cancer. New biomarkers for diagnostics and therapy].Pathologe. 2015 Nov;36 Suppl 2:189-93. doi: 10.1007/s00292-015-0084-1. Pathologe. 2015. PMID: 26391246 Review. German.
-
CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain.Int J Mol Sci. 2013 Jan 15;14(1):1713-27. doi: 10.3390/ijms14011713. Int J Mol Sci. 2013. PMID: 23322021 Free PMC article. Review.
References
-
- <References>. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al.. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012;123(2):205–22. https://pubmed.ncbi.nlm.nih.gov/22212630/. doi: 10.1007/s00401-011-0933-9 - DOI - PubMed
-
- Che W, Liu J, Fu T, Wang X, Lyu J. Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience. Curr Oncol. 2022;29(11):8374–89. https://pubmed.ncbi.nlm.nih.gov/36354720/. doi: 10.3390/curroncol29110660 - DOI - PMC - PubMed
-
- Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705. https://pubmed.ncbi.nlm.nih.gov/12173339/. doi: 10.1002/cncr.10541 - DOI - PubMed
-
- Merkin RD, Chiang VL, Goldberg SB. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances in Medical Oncology. 2023;15:17588359231175438. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233588/. doi: 10.1177/17588359231175438 - DOI - PMC - PubMed
-
- Wang G, Xu J, Qi Y, Xiu J, Li R, Han M. Distribution Of Brain Metastasis From Lung Cancer. Cancer Manag Res. 2019;11:9331–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830371/. doi: 10.2147/CMAR.S222920 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials